7 Min Read ZURICH (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine as they investigate rare blood clotting in six women, including one who died. Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez J&J also said it was delaying the rollout of its vaccine in Europe. U.S. officials said the temporary halt is expected only to last a few days. The move comes after Europe’s drug regulator said it had found a possible link between AstraZeneca’s COVID-19 vaccine and very rare blood clots in some adults who had received the shot.